Your search for apixaban returned 43 results

No substantial differences seen for other outcomes or for other direct oral anticoagulant comparisons

Fewer compliance events seen with apixaban versus enoxaparin for extended-duration VTE prophylaxis after abdominopelvic oncologic surgery

Apixaban is a direct oral anticoagulant that relies less on kidney excretion.

Among new users, rates of recurrent venous thromboembolism, GI and intracranial bleeding lower with apixaban than rivaroxaban

Improved communication with patients about cost, bleeding, and monitoring may increase compliance

Apixaban the only direct oral anticoagulant linked to lower adverse event rates than warfarin for patients with atrial fibrillation across frailty levels

Kidney injury may be less among patients with chronic kidney disease and atrial fibrillation taking apixaban versus warfarin for anticoagulation, new research suggests.

Lower rates seen for ischemic stroke or systemic embolism, GI bleeding or intracranial hemorrhage.

Less knowledge about OTC products with potentially serious interactions linked to increased use

Among patients with cancer starting chemotherapy who are at intermediate-to-high risk, rates of venous thromboembolism are significantly lower for thromboprophylaxis with apixaban vs placebo.